GLP-1 receptor agonists are used in line with NICE guidance for certain people with type 2 diabetes (NICE NG28) and, in defined circumstances, for weight management (NICE TA875)
Its safety profile was comparable to that of other medications in the GLP-1 receptor agonist class
Clinical Trials: Mixed Evidence and Opportunities for Future Design Enhancements Although there is now three decades worth of solid laboratory evidence suggesting that glutathione supplementation can address symptoms in Parkinsons disease patients, the results from the few clinical studies that have been conducted are somewhat less convincing
Side Effects and Safety Concerns GHK-Cu safety depends on route, formulation, dose, product quality, population, and whether the use is cosmetic, clinical, compounded, or investigational [8], [11]